DARE
NASDAQ · Pharmaceuticals
Dare Bioscience Inc
$1.36
+0.06 (+4.62%)
Financial Highlights (FY 2026)
Revenue
17.1K
Net Income
-6,815,961
Gross Margin
100.0%
Profit Margin
-41,447.9%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 44.5% | 44.5% | 44.5% |
| Operating Margin | -31,412.2% | 19.8% | 16.7% | 17.2% |
| Profit Margin | -41,447.9% | 14.8% | 17.9% | 15.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 17.1K | 6.97M | 6.37M | 6.18M |
| Gross Profit | 17.1K | 3.10M | 2.84M | 2.75M |
| Operating Income | -5,386,244 | 1.38M | 1.06M | 1.06M |
| Net Income | -6,815,961 | 1.03M | 1.14M | 939.3K |
| Gross Margin | 100.0% | 44.5% | 44.5% | 44.5% |
| Operating Margin | -31,412.2% | 19.8% | 16.7% | 17.2% |
| Profit Margin | -41,447.9% | 14.8% | 17.9% | 15.2% |
| Rev Growth | — | +17.6% | +7.5% | -4.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 9.38M | 9.41M | 9.16M |
| Total Equity | — | 13.47M | 13.13M | 13.27M |
| D/E Ratio | — | 0.70 | 0.72 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -6,745,944 | 1.81M | 1.58M | 1.73M |
| Free Cash Flow | — | 730.8K | 772.3K | 654.4K |